Exciting Milestones for Endotronics, Heart Failure Monitoring Medtech company, in 2024
– January 5, 2024: Endotronix submitted its Premarket Approval (PMA) application to the FDA for the Cordella™ Pulmonary Artery (PA) Pressure Sensor System. This marks a significant step towards enhancing heart failure management with innovative remote monitoring solutions. [Learn more here].
– June 24, 2024: The FDA granted Premarket Approval for the Cordella™ PA Sensor System, recognizing its potential to transform heart failure care by providing proactive management and reducing hospitalizations. This approval sets the stage for its commercial launch in the U.S. later this year. [Read the full article].
– July 25, 2024: In a strategic move, Edwards Lifesciences announced the acquisition of Endotronix, among another company, in a deal valued at $1.6 billion. This acquisition underscores the potential of Cordella™ and other medtech innovations to reshape cardiac care. [More details here].